
Elon Musk’s DOGE Disaster Will Likely Cost Taxpayers Nearly 4 Times More Than It Cut
If you're very rich, cheating on your taxes will be easier to get away with. That's something. If you're very rich.
If you're very rich, cheating on your taxes will be easier to get away with. That's something. If you're very rich.
This complete system built for lawyers simplifies the complex world of law firm finance.
With comprehensive planning, retirement becomes not an ending but a transition to a rewarding new phase of life.
Roche said it will expand existing sites and construct new U.S. manufacturing and R&D infrastructure in areas such as gene therapy and cardiometabolic disease. The plans follow U.S. capital expenditure announcements from several big pharmaceutical companies.
Signs point to yes. Or no. But definitely, one of those two.
The two Italian fashion pillars are coming together.
Position your firm for long-term growth with better financial visibility and control. Learn how to track performance, manage spending, and plan strategically—download the full e-book now.
Presidency by jump scare does not seem to be going so well.
Health tech companies made several major funding announcements in March. Here is a list of some of the biggest funding rounds.
Welcome to hell, here's your meme stock prospectus.
Backdating moral outrage is what got Democrats into the terrible situation they're now in in the first place.
These tools demonstrate that information is power.
A month before 23andMe’s bankruptcy filing, CEO Anne Wojcicki had a fully financed proposal to take the genetic testing company private. The financing fell apart, and a series of alternative proposals by Wojcicki did not result in a deal.
Amid the market volatility and intense macroeconomic uncertainty, is it wise for Hinge Health to test the public markets?
You still have time to make a significant impact on your tax situation and long-term financial health.
Apparently forgetting that it is not opposite day, almost everything Trump is trying to do will raise, not lower, prices for consumers.
Many experts — be they venture capitalists or private equity investors — shared their advice with biotech entrepreneurs navigating a tough funding environment.